论文部分内容阅读
近年来生物制剂的应用为类风湿性关节炎(rheumatoid arthritis,RA)的治疗增添了新的手段,取得了很好的临床疗效,但应用本品的风险也应引起足够的重视。现将我科在使用依那西普(益赛普)治疗RA的过程中出现的肺部感染病例报道如下。病例1:患者,女,50岁。2010年5月6日以“反复四肢关节疼痛4年,咳嗽,咯痰1周”入院。简要病史:4年前无明显诱因出现双肩、双肘、双手
In recent years, the application of biological agents has added new measures for the treatment of rheumatoid arthritis (RA) and achieved good clinical efficacy. However, the risks of using this product should also be given enough attention. Now my department in the use of etanercept (ipsa) in the treatment of RA in the process of pulmonary infection are reported as follows. Case 1: Patient, female, 50 years old. May 6, 2010 to “four-legged joint pain repeatedly, cough, expectoration for a week ” admission. Brief history: 4 years ago no obvious incentive to appear shoulders, elbows, hands